Ethical Business | Novartis

Novartis provides update on RUXCOVID study of ruxolitinib for hospitalized patients with COVID-19

Basel, December 14, 2020 — Novartis today announced that the Phase III RUXCOVID study evaluating ruxolitinib on top of standard of care (SoC) therapy compared to SoC treatment alone in patients with COVID-19 did not meet its primary endpoint1. Initial data show there was no statistically significant reduction in the proportion of patients on…

Infectious DiseasesEthical Business
Novartis pledges 10-year commitment with Morehouse School of Medicine, 26 Historically Black Colleges, Universities, Medical Schools and other leading organizations to co-create effective, measurable solutions for health equity

Basel, July 20, 2021 — Novartis and the Novartis US Foundation today announced a planned 10-year collaboration with Coursera, the National Medical Association, Thurgood Marshall College Fund, Morehouse School of Medicine and 26 additional Historically Black Colleges, Universities and Medical Schools (HBCUs) to co-create programs that address the…

Social CommitmentGlobal Health PartnershipsFuture of HealthcareEthical Business
Novartis provides update on RUXCOVID study of ruxolitinib for hospitalized patients with COVID-19

Basel, December 14, 2020 — Novartis today announced that the Phase III RUXCOVID study evaluating ruxolitinib on top of standard of care (SoC) therapy compared to SoC treatment alone in patients with COVID-19 did not meet its primary endpoint1. Initial data show there was no statistically significant reduction in the proportion of patients on…

Infectious DiseasesEthical Business
Novartis Resolves Legacy FCPA Investigations

Basel, June 25, 2020 – Novartis has reached settlements with the US Department of Justice (DOJ) and the US Securities and Exchange Commission (SEC) resolving all Foreign Corrupt Practices Act (FCPA) investigations into historical conduct by the Company and its subsidiaries. As part of the settlements, Novartis and certain of its current and former…

Social CommitmentReimagine MedicineEthical BusinessAd Hoc
Novartis resolves legacy litigation matters, finalizing settlement of speaker program litigation with Government in the US and positioning company for the future by fully scaling its next-generation digital engagement technologies

Basel, July 2, 2020 – Novartis has finalized its previously disclosed agreement with the US Attorney’s Office for the Southern District of New York, the New York State Attorney General, and relator Oswald Bilotta resolving a civil suit challenging speaker programs and other promotional events conducted from 2002 through 2011 by Novartis…

Reimagine MedicineEthical BusinessAd Hoc
Novartis launches first-of-its-kind not-for-profit portfolio of medicines for symptomatic treatment of COVID-19

Basel, July 16, 2020 — Today, Novartis announced a new initiative to help patients in low-income and lower-middle-income countries (LIC; LMIC) access affordable medicines to treat the major symptoms of COVID-19 – a critical need in the absence of a vaccine or curative treatment. Inflammation and respiratory problems linked to COVID-19 can cause…

Reimagine MedicineEthical BusinessAccess to Healthcare
Novartis announces ambitious ESG targets to increase access to medicines and achieve full carbon neutrality

Basel, September 1, 2020 — Novartis will host a virtual investor event today to provide a comprehensive overview of the company’s progress in its Environmental, Social and Governance (ESG) strategy.

Novartis AccessFuture of HealthcareEthical BusinessAd HocAccess to Healthcare
Access to Healthcare

In your neighborhood: a community-based approach to health equity in the US

Patrice Matchaba shares how a lifetime of experience helped shape an effort to address healthcare disparities.

Access to HealthcareEthical BusinessSocial Commitment
Access to Healthcare

Doing the right thing is good business

Lutz Hegemann shares how lessons learned treating patients with leprosy influenced the way he thinks about the pharmaceutical business.

Access to HealthcareDiseasesEthical BusinessSocial Commitment
Access to Healthcare

Positive gains are needed to accelerate change for women with lung disease

COPD receives low attention as a women’s health issue. It’s time to change that.

Chronic IllnessDisease AwarenessEthical BusinessRespiratoryWomen in Science
From Our Labs

Sleuths use hi-tech sensors to fight pharmaceutical crime

Novartis is working to tackle the problem of counterfeit drugs, which are a threat to patient health.

DigitalEthical BusinessMedicine Safety
From Our Labs

Women in Science: Jean Silveri

Jean Silveri shares key insights from her legal career.

Ethical BusinessNovartis Institutes for BioMedical ResearchWomen in ScienceWorking at NovartisCareers